Get the Stockscreener App
2.04
2.86%
-0.06
After Hours:
2.10
0.06
+2.94%
Palisade Bio Inc stock is traded at $2.04, with a volume of 4.08M.
It is down -2.86% in the last 24 hours and up +17.24% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$2.10
Open:
$2.1
24h Volume:
4.08M
Relative Volume:
1.01
Market Cap:
$354.51M
Revenue:
$250.00K
Net Income/Loss:
$-24.15M
P/E Ratio:
-1.9144
EPS:
-1.0656
Net Cash Flow:
$-12.40M
1W Performance:
-8.52%
1M Performance:
+17.24%
6M Performance:
+6.25%
1Y Performance:
+181.38%
1-Day Range:
$2.035
$2.22
1-Week Range:
$1.96
$2.29
52-Week Range:
$0.53
$2.855
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
2.04 | 363.20M | 250.00K | -24.15M | -12.40M | -1.0656 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-26-26 | Initiated | H.C. Wainwright | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-09-26 | Initiated | B. Riley Securities | Buy |
| Dec-29-25 | Initiated | Piper Sandler | Overweight |
Palisade Bio Inc Stock (PALI) Latest News
H.C. Wainwright reiterates Palisade Bio stock rating on FDA trial clearance - Investing.com Nigeria
Enterprise value to revenue forward of Palisade Bio, Inc. – BOATS:PALI - TradingView
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally? - Stocktwits
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Enterprise value to EBIT forward of Palisade Bio, Inc. – NASDAQ:PALI - TradingView
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 2500 Growth Benchmark - marketscreener.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 2000 Index - marketscreener.com
Palisade Bio Receives FDA Clearance Of IND For PALI-2108 And Plans To Initiate Global Phase 2 ASCENTRA-UC Study In Ulcerative Colitis - marketscreener.com
Palisade Bio stock surges on FDA clearance for UC trial - Investing.com
Palisade Bio stock surges on FDA clearance for UC trial By Investing.com - Investing.com South Africa
Enterprise value to EBIT forward of Palisade Bio, Inc. – BOATS:PALI - TradingView
PALI Stock Climbs As Palisade Bio Loads Up Dealmakers - StocksToTrade
PALI Stock Grinds Higher As Pipeline And Board Upgrades Draw Trader Focus - timothysykes.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 2000 Value Benchmark - marketscreener.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell Microcap Value Benchmark Index - marketscreener.com
Palisade Bio receives FDA clearance for ulcerative colitis trial - Investing.com
Palisade Bio receives FDA clearance for ulcerative colitis trial By Investing.com - Investing.com Canada
Palisade Bio clears FDA hurdle for ulcerative colitis trial - Stock Titan
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 2000 Growth Benchmark - marketscreener.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 3000E Growth Benchmark - marketscreener.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell Microcap Index - marketscreener.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 3000 Index - marketscreener.com
Palisade Bio, Inc. Actuals & Estimates (FWB:7NS0) - TradingView
Palisade Bio Inc (PALI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Palisade Bio, Inc. Actuals & Estimates (NASDAQ:PALI) - TradingView
PALI Forecast — Price Target — Prediction for 2027 - TradingView
Palisade Bio Inc (PALI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Palisade Bio Inc (PALI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Director at Palisade Bio (PALI) granted 336,904 RSUs with three-year vesting - Stock Titan
Palisade Bio (PALI) director Robert Baltera Jr. files initial Form 3 - Stock Titan
Palisade Bio Inc (PALI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Palisade Bio Inc (PALI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Palisade Bio Inc (PALI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Palisade Bio Inc (PALI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Palisade Bio Inc (PALI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Palisade Bio (PALI) director Jordan Michael Zwick files baseline Form 3 - Stock Titan
Palisade Bio (PALI) director gets 592,300 RSU grant and 20,200 RSUs vest - Stock Titan
Palisade Bio (PALI) director reports major RSU grant and new share holdings - Stock Titan
Palisade Bio (PALI) director Emil Chuang reports new RSU awards - Stock Titan
Palisade Bio (PALI) Holds Steady Near Key Support After Modest GainTriple Top - lwvtexas.org
Palisade Bio, Inc. Approves Amendments to Equity Incentive and Employee Stock Purchase Plans at 2026 Annual Meeting – Minichart - Minichart
Palisade Bio (PALI) director receives 336,904 RSUs in equity grant - Stock Titan
Palisade Bio Shareholders Approve Charter Amendments, Governance Matters - TipRanks
Palisade Bio (PALI) raises authorized shares to 450M and refreshes equity plans - Stock Titan
Palisade Bio adds two directors with biotech expertise - Investing.com
Palisade Bio adds two directors with biotech expertise By Investing.com - Investing.com Australia
Palisade Bio Continues to Build on PALI-2108 Clinical Progress as It Advances Toward Phase 2 Development >PALI - Moomoo
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors - GlobeNewswire
PALI Q1 2026 Earnings: Net Loss Wider Than Estimates as Pre-Revenue Biotech Advances PipelineSpecial Dividend Alert - newsline.com
Palisade Bio, Inc. to Present on PDE4 Inhibitor Prodrug Approach for Fibrostenotic Crohn's Disease at NYAS Symposium - Quiver Quantitative
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Palisade Bio Inc Stock (PALI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Finley John David | CEO, CFO |
Feb 12 '26 |
Sale |
1.75 |
3,896 |
6,818 |
27,353 |
| Williams Donald Allen | Director |
Jan 16 '26 |
Buy |
1.67 |
5,000 |
8,356 |
10,728 |
| Williams Donald Allen | Director |
Jan 09 '26 |
Buy |
1.88 |
5,000 |
9,400 |
5,728 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):